{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:43Z","timestamp":1793726083282,"version":"4.6.1"},"reference-count":143,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272619"],"award-info":[{"award-number":["82272619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010428","name":"Innovation and Technology Fund","doi-asserted-by":"publisher","award":["GHP\/086\/21GD"],"award-info":[{"award-number":["GHP\/086\/21GD"]}],"id":[{"id":"10.13039\/501100010428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.scib.2026.04.048","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:09:42Z","timestamp":1776899382000},"page":"2916-2932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues"],"prefix":"10.1016","volume":"71","author":[{"given":"Suki","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2026.04.048_b0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.scib.2026.04.048_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0020","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.scib.2025.12.022","article-title":"Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries\/territories in 2022","volume":"71","author":"Li","year":"2026","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2026.04.048_b0030","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.scib.2026.04.048_b0035","doi-asserted-by":"crossref","first-page":"32345","DOI":"10.1074\/jbc.M313478200","article-title":"Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease","volume":"279","author":"Samuel","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.scib.2026.04.048_b0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.scib.2026.04.048_b0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0050","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2026.04.048_b0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-025-09190-w","article-title":"Kupffer cell programming by maternal obesity triggers fatty liver disease","volume":"644","author":"Huang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.04.048_b0060","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20150405","article-title":"The balance between IL-17 and IL-22 produced by liver-infiltrating T helper cells critically controls NASH development in mice","volume":"130","author":"Rolla","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.scib.2026.04.048_b0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.04.048_b0075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.scib.2026.04.048_b0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.04.048_b0085","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.cmet.2024.07.013","article-title":"Integrative clinical and preclinical studies identify ferroterminator1 as a potent therapeutic drug for MASH","volume":"36","author":"Tao","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.scib.2026.04.048_b0090","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/j.scib.2024.09.019","article-title":"Essentiality of SLC7A11-mediated nonessential amino acids in MASLD","volume":"69","author":"Shen","year":"2024","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2026.04.048_b0095","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0100","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jhep.2008.12.025","article-title":"Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins","volume":"50","author":"Makkonen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100728","article-title":"African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population","volume":"27","author":"Cavalcante","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0115","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.scib.2026.04.048_b0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 c >g polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.scib.2026.04.048_b0130","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2026.04.048_b0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s42255-024-01177-7","article-title":"Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis","volume":"7","author":"Zhang","year":"2025","journal-title":"Nat Metab"},{"key":"10.1016\/j.scib.2026.04.048_b0140","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/gutjnl-2024-333154","article-title":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy","volume":"74","author":"Zhang","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.scib.2026.04.048_b0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"Rs641738C>T near MBOAT7 is associated with liver fat, ALT, and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0150","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0155","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0160","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/apt.17638","article-title":"The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma","volume":"58","author":"Innes","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.scib.2026.04.048_b0165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eng.2024.04.018","article-title":"Carboxyl ester lipase protects against metabolic dysfunction-associated steatohepatitis by binding to fatty acid synthase","volume":"41","author":"Song","year":"2024","journal-title":"Engineering"},{"key":"10.1016\/j.scib.2026.04.048_b0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jhep.2017.03.017","article-title":"O-glcnac transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress","volume":"67","author":"Xu","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9840","article-title":"Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target","volume":"10","author":"Liu","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.scib.2026.04.048_b0180","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","article-title":"Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis","volume":"31","author":"Ye","year":"2024","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.scib.2026.04.048_b0185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","article-title":"Analysis of the expression of PRDX6 in patients with hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells","volume":"25","author":"Mu","year":"2024","journal-title":"Curr Genomics"},{"key":"10.1016\/j.scib.2026.04.048_b0190","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429260902230925044009","article-title":"Screening and identification of ESR1 as a target of icaritin in hepatocellular carcinoma: evidence from bibliometrics and bioinformatic analysis","volume":"17","author":"Zhou","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.scib.2026.04.048_b0195","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/s41467-021-27539-3","article-title":"The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2026.04.048_b0200","article-title":"METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.scib.2026.04.048_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.adp4120","article-title":"Liver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling","volume":"387","author":"Ding","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.scib.2026.04.048_b0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12943-020-01239-w","article-title":"ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1","volume":"19","author":"Chen","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.scib.2026.04.048_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-022-00370-2","article-title":"ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner","volume":"12","author":"Wang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.scib.2026.04.048_b0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41420-022-01234-8","article-title":"LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.scib.2026.04.048_b0225","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2023.2204772","article-title":"m6A-modification regulated circ-CCT3 acts as the sponge of miR-378a-3p to promote hepatocellular carcinoma progression","volume":"18","author":"Liu","year":"2023","journal-title":"Epigenetics"},{"key":"10.1016\/j.scib.2026.04.048_b0230","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0235","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jhep.2022.03.015","article-title":"Unique molecular characteristics of NAFLD-associated liver cancer accentuate \u03b2-catenin\/TNFRSF19-mediated immune evasion","volume":"77","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0240","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2020.09.032","article-title":"Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features","volume":"74","author":"Zhu","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0245","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41586-024-08317-9","article-title":"FBP1 controls liver cancer evolution from senescent MASH hepatocytes","volume":"637","author":"Gu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.04.048_b0250","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3350\/cmh.2020.0125","article-title":"Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0255","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/nu17132145","article-title":"The association between Prevotella copri and advanced fibrosis in the progression of metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Zhang","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.scib.2026.04.048_b0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2026.04.048_b0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.scib.2026.04.048_b0270","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.scib.2026.04.048_b0275","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","article-title":"The fecal mycobiome in non-alcoholic fatty liver disease","volume":"76","author":"Demir","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1902719","article-title":"The gut microbiota metabolite capsiate promotes Gpx4 expression by activating TRPV1 to inhibit intestinal ischemia reperfusion-induced ferroptosis","volume":"13","author":"Deng","year":"2021","journal-title":"Gut Microbes"},{"key":"10.1016\/j.scib.2026.04.048_b0285","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.chom.2023.04.002","article-title":"Liberation of daidzein by gut microbial \u03b2-galactosidase suppresses acetaminophen-induced hepatotoxicity in mice","volume":"31","author":"Zeng","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.scib.2026.04.048_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585880","article-title":"Tumor necrosis factor receptors: pleiotropic signaling complexes and their differential effects","volume":"11","author":"Gough","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2026.04.048_b0295","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70022","article-title":"HLF and PPAR\u03b1 axis regulates metabolic-associated fatty liver disease through extracellular vesicles derived from the intestinal microbiota","volume":"4","author":"Yang","year":"2025","journal-title":"Imeta"},{"key":"10.1016\/j.scib.2026.04.048_b0300","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.scib.2026.04.048_b0305","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1148\/radiol.13121360","article-title":"Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy","volume":"267","author":"Idilman","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.scib.2026.04.048_b0310","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0315","first-page":"347","article-title":"A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis","volume":"63","author":"Grigorescu","year":"2012","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.scib.2026.04.048_b0320","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cca.2017.08.022","article-title":"Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis","volume":"473","author":"Qi","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.scib.2026.04.048_b0325","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.scib.2026.04.048_b0330","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0335","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1478-3231.2005.01064.x","article-title":"Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"25","author":"Suzuki","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.scib.2026.04.048_b0340","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.26030","article-title":"Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"57","author":"Tanwar","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0345","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/CM9.0000000000002027","article-title":"Non-invasive tests of non-alcoholic fatty liver disease","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.scib.2026.04.048_b0350","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0355","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ajg.2016.65","article-title":"Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study","volume":"111","author":"Loomba","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.scib.2026.04.048_b0360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.scib.2026.04.048_b0365","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.scib.2026.04.048_b0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-5926-4-10","article-title":"The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis","volume":"4","author":"Poynard","year":"2005","journal-title":"Comp Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0375","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0380","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","article-title":"Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese","volume":"121","author":"Dixon","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0385","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Feldstein","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.scib.2026.04.048_b0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1478-3231.2005.01209.x","article-title":"Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease","volume":"26","author":"Palekar","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.scib.2026.04.048_b0395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-230X-6-34","article-title":"Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Poynard","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.scib.2026.04.048_b0400","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0405","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0410","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2018-317584","article-title":"Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease","volume":"68","author":"Caussy","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.scib.2026.04.048_b0415","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0420","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0425","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2024.09.008","article-title":"A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis","volume":"168","author":"Marsh","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0430","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3350\/cmh.2024.1038","article-title":"GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0435","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","article-title":"An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations","volume":"78","author":"Carr","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0440","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2026.04.048_b0445","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal virome signature associated with severity of nonalcoholic fatty liver disease","volume":"159","author":"Lang","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111738","article-title":"Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p","volume":"387","author":"Zhao","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.scib.2026.04.048_b0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142661","article-title":"Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis","volume":"10","author":"Becker","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.scib.2026.04.048_b0460","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2201159","article-title":"A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma","volume":"15","author":"Yang","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.scib.2026.04.048_b0465","article-title":"Five miRNAs identified in fucosylated extracellular vesicles as non-invasive diagnostic signatures for hepatocellular carcinoma","volume":"5","author":"Li","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.scib.2026.04.048_b0470","article-title":"Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy","author":"Lee","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0475","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-026-00892-5","article-title":"Peripheral blood biomarkers for predicting response to PD-1\/PD-L1 inhibitors","volume":"14","author":"Chen","year":"2026","journal-title":"Biomark Res"},{"key":"10.1016\/j.scib.2026.04.048_b0480","unstructured":"Younossi ZM, de Avila L, Petta S, et al. Global performance of non-invasive tests in MASLD: insights from the MASLD study. Hepatology 2025;online ahead of print."},{"key":"10.1016\/j.scib.2026.04.048_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.medp.2025.100096","article-title":"Revisiting the role of liver cirrhosis in surgical treatment for hepatocellular carcinoma","volume":"2","author":"Ke","year":"2025","journal-title":"Medicine Plus"},{"key":"10.1016\/j.scib.2026.04.048_b0490","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100196","article-title":"Key takeaways from the updated multidisciplinary European MASLD guidelines","volume":"3","author":"Horn","year":"2025","journal-title":"eGastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0495","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0500","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2026.04.048_b0505","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0510","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.jhep.2025.03.022","article-title":"Resmetirom directly inhibits lipid accumulation in human liver-derived organoids","volume":"83","author":"Li","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0515","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.scib.2026.04.048_b0520","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/thy.2021.0621","article-title":"Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary mouse model of nonalcoholic steatohepatitis","volume":"32","author":"Zhou","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.scib.2026.04.048_b0525","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1286593","article-title":"Cross-talk between the gut microbiota and hypothyroidism: a bidirectional two-sample Mendelian randomization study","volume":"11","author":"Shi","year":"2024","journal-title":"Front Nutr"},{"key":"10.1016\/j.scib.2026.04.048_b0530","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0535","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.scib.2026.04.048_b0540","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2026.04.048_b0545","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0550","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0555","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2026.04.048_b0560","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.scib.2026.04.048_b0565","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPAR\u03b2\/\u03b4 and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.scib.2026.04.048_b0570","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0575","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0580","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2026.04.048_b0585","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0590","doi-asserted-by":"crossref","first-page":"S1217","DOI":"10.14309\/01.ajg.0001036044.63596.59","article-title":"Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial","volume":"119","author":"Noureddin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.scib.2026.04.048_b0595","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.04.048_b0600","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.scib.2026.04.048_b0605","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","article-title":"Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"79","author":"Li","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0610","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1136\/gutjnl-2023-331117","article-title":"Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma","volume":"73","author":"Wen","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.scib.2026.04.048_b0615","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jhep.2023.06.021","article-title":"Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis","volume":"79","author":"Wang","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0620","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429310703240823045808","article-title":"Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation","volume":"17","author":"Sensi","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.scib.2026.04.048_b0625","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0630","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.scib.2026.04.048_b0635","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2026.04.048_b0640","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.scib.2026.04.048_b0645","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.04.048_b0650","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.scib.2026.04.048_b0660","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/oby.22700","article-title":"Genetically engineered Escherichia coli Nissle 1917 secreting GLP-1 analog exhibits potential antiobesity effect in high-fat diet-induced obesity mice","volume":"28","author":"Ma","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.scib.2026.04.048_b0665","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.22445","article-title":"Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents","volume":"48","author":"Nicaise","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2026.04.048_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104952","article-title":"Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid","volume":"100","author":"Lau","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.scib.2026.04.048_b0675","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eng.2022.10.010","article-title":"Pien Tze Huang protects against non-alcoholic steatohepatitis by modulating the gut microbiota and metabolites in mice","volume":"35","author":"Zeng","year":"2024","journal-title":"Engineering"},{"key":"10.1016\/j.scib.2026.04.048_b0680","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2026.04.048_b0685","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","article-title":"Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid","volume":"8","author":"Wei","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.scib.2026.04.048_b0690","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of PD-1 therapy in MAFLD-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.scib.2026.04.048_b0695","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2697","article-title":"D-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma","volume":"9","author":"Han","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.scib.2026.04.048_b0700","article-title":"Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2026.04.048_b0705","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s12276-023-01102-0","article-title":"Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating L-arginine production","volume":"55","author":"Kim","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.scib.2026.04.048_b0710","article-title":"Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota","volume":"9","author":"Cao","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.scib.2026.04.048_b0715","doi-asserted-by":"crossref","first-page":"13997","DOI":"10.3390\/ijms241813997","article-title":"Lactiplantibacillus plantarum LPJZ-658 improves non-alcoholic steatohepatitis by modulating bile acid metabolism and gut microbiota in mice","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927326004482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927326004482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:57:21Z","timestamp":1785880641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927326004482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":143,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2095927326004482"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2026.04.048","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2026.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. and Science China Press.","name":"copyright","label":"Copyright"}]}}